Kevin P Hill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/276429/publications.pdf

Version: 2024-02-01

45 1,399 16
papers citations h-index

16 36
h-index g-index

47 47 docs citations

47 times ranked 1976 citing authors

#	Article	IF	CITATIONS
1	Workplace Cannabis Policies: A Moving Target. Cannabis and Cannabinoid Research, 2022, 7, 16-23.	2.9	5
2	What gets resident physicians stressed and how would they prefer to be supported? A best–worst scaling study. Postgraduate Medical Journal, 2022, 98, 930-935.	1.8	7
3	Buprenorphine in safety-sensitive positions. American Journal of Drug and Alcohol Abuse, 2022, , 1-5.	2.1	1
4	Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. American Journal of Psychiatry, 2022, 179, 98-109.	7.2	42
5	Teaching Residents to Treat Substance Use Disorders: Overcoming 10 Common Patient-Perceived Barriers to Outpatient Treatment Engagement. Academic Psychiatry, 2021, 45, 217-221.	0.9	2
6	Should You Recommend Cannabinoids for This Patient With Painful Neuropathy?. Annals of Internal Medicine, 2021, 174, 237-246.	3.9	1
7	Self-Reported Preferences for Help-Seeking and Barriers to Using Mental Health Supports Among Internal Medicine Residents: Exploratory Use of an Econometric Best-Worst Scaling Framework for Gathering Physician Wellness Preferences. JMIR Medical Education, 2021, 7, e28623.	2.6	O
8	A cannabis oracle? Delphi method not a substitute for randomized controlled trials of cannabinoids as therapeutics. Journal of Cannabis Research, 2021, 3, 23.	3.2	3
9	Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. Journal of General Internal Medicine, 2021, 36, 2074-2084.	2.6	40
10	How Emergency Physicians Approach Refusal of Observation after Naloxone Resuscitation. Journal of Emergency Medicine, 2020, 58, 148-159.	0.7	4
11	Denoising scanner effects from multimodal MRI data using linked independent component analysis. Neurolmage, 2020, 208, 116388.	4.2	32
12	Care of the Patient Using Cannabis. Annals of Internal Medicine, 2020, 173, ITC65-ITC80.	3.9	3
13	Commentary: Proposed Model State Cannabis Laws to Reduce Harms. American Journal on Addictions, 2020, 29, 426-427.	1.4	0
14	Advocacy and Public Policy Efforts of the American Academy of Addiction Psychiatry. American Journal on Addictions, 2020, 29, 401-406.	1.4	1
15	Cannabinoids and the Coronavirus. Cannabis and Cannabinoid Research, 2020, 5, 118-120.	2.9	26
16	The Molecular-Container Calabadion-2 Prevents Methamphetamine-Induced Reinstatement in Rats: A Potential Approach to Relapse Prevention?. International Journal of Neuropsychopharmacology, 2020, 23, 401-405.	2.1	3
17	Clinical uses of cannabis and cannabinoids in the United States. Journal of the Neurological Sciences, 2020, 411, 116717.	0.6	60
18	Medical Use of Cannabis in 2019. JAMA - Journal of the American Medical Association, 2019, 322, 974.	7.4	49

#	Article	IF	Citations
19	Review: Nonâ€Invasive Brain Stimulation in Behavioral Addictions: Insights from Direct Comparisons With Substance Use Disorders. American Journal on Addictions, 2019, 28, 431-454.	1.4	12
20	Priority Considerations for Medicinal Cannabis-Related Research. Cannabis and Cannabinoid Research, 2019, 4, 139-157.	2.9	21
21	Therapeutic cannabis use in 2018: where do we stand?. Lancet Psychiatry, the, 2019, 6, 88-89.	7.4	5
22	Cannabis and the Current State of Treatment for Cannabis Use Disorder. Focus (American Psychiatric) Tj ETQq0	0 0 rgBT /0	Ovgrlock 10 T
23	Cannabis legalisation in Canada: a crucial trial balloon. Lancet Psychiatry,the, 2019, 6, 5-6.	7.4	10
24	Cannabis for the Treatment of Chronic Pain in the Era of an Opioid Epidemic: A Symposium-Based Review of Sociomedical Science. Pain Medicine, 2019, 20, 2311-2323.	1.9	13
25	Cannabis Legalization and Psychiatric Disorders: Caveat "Hemp-tor― Canadian Journal of Psychiatry, 2018, 63, 447-450.	1.9	14
26	The Role of Cannabis Legalization in the Opioid Crisis. JAMA Internal Medicine, 2018, 178, 679.	5.1	16
27	Cannabis and Mood Disorders. Current Addiction Reports, 2018, 5, 336-345.	3.4	30
28	Cannabis and Pain: A Clinical Review. Cannabis and Cannabinoid Research, 2017, 2, 96-104.	2.9	172
29	Cannabis Use and Risk for Substance Use Disorders and Mood or Anxiety Disorders. JAMA - Journal of the American Medical Association, 2017, 317, 1070.	7.4	28
30	Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. American Journal on Addictions, 2017, 26, 795-801.	1.4	42
31	Recreational cannabis legalisation: details will determine mental health effects. Lancet Psychiatry,the, 2016, 3, 798-799.	7.4	4
32	Minimal Physical Health Risk Associated With Long-term Cannabis Use—But Buyer Beware. JAMA - Journal of the American Medical Association, 2016, 315, 2338.	7.4	13
33	Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems. JAMA - Journal of the American Medical Association, 2015, 313, 2474.	7.4	419
34	Medical marijuana does not increase adolescent marijuana use. Lancet Psychiatry,the, 2015, 2, 572-573.	7.4	1
35	Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series. Journal of Opioid Management, 2015, 11, 363-366.	0.5	11
36	Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. Drug and Alcohol Dependence, 2014, 145, 121-126.	3.2	90

#	Article	IF	CITATIONS
37	Medical Marijuana. Journal of Psychiatric Practice, 2014, 20, 389-391.	0.7	14
38	Behavioral Interventions and Pharmacotherapies for Cannabis Use Disorder. Current Treatment Options in Psychiatry, 2014, 1, 163-174.	1.9	5
39	Association of cannabis use with opioid outcomes among opioid-dependent youth. Drug and Alcohol Dependence, 2013, 132, 342-345.	3.2	24
40	Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Dual Nicotine and Cannabis Dependence: A Pilot Study. American Journal on Addictions, 2013, 22, 233-238.	1.4	36
41	After detoxification: levels of treatment for alcohol dependence. American Family Physician, 2013, 88, 576.	0.1	0
42	Diagnosing and treating opioid dependence. Journal of Family Practice, 2012, 61, 588-97.	0.2	2
43	Reply: Response to Letter to the Editor. Neuropsychopharmacology, 2008, 33, 2044-2044.	5.4	0
44	The ADVANTAGE Seeding Trial: A Review of Internal Documents. Annals of Internal Medicine, 2008, 149, 251.	3.9	113
45	Biological Treatments for Amfetamine Dependence. CNS Drugs, 2007, 21, 851-869.	5.9	16